LO
LOVFF.US Cannara Biotech Inc
- Market cap
- USD 141M
- P/E
- 17.9x
- P/B
- 1.60x
- ROE
- 8.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to May 2026.
Is LOVFF.US undervalued?
Graham numberLOVFF.US trades 12.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cannara Biotech Inc fundamental analysis
No fundamental analysis for Cannara Biotech Inc yet.
Cannara Biotech Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cannara Biotech Inc
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name. The company sells its products through wholesalers and online merchandisers. In addition, it engages in the real estate operations. Cannara Biotech Inc. was in…
Full company profileCannara Biotech Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to May 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cannara Biotech Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 433K | 2.10M | 2.47M | 16.3M | 35.8M | 57.3M | 81.7M | 107M | 119M |
| Gross Profit | 159K | 1.69M | 1.15M | 9.57M | 17.3M | 27.2M | 29.8M | 47.1M | 50.5M |
| Operating Income | -1.82M | -10.2M | -11.9M | 299K | 4.98M | 12.0M | 8.04M | 21.8M | 17.9M |
| EBITDA | -1.68M | -10.9M | -9.19M | 3.06M | 8.14M | 16.4M | 15.7M | 28.5M | 23.8M |
| Net Income | -2.11M | -12.3M | -12.5M | -1.53M | 2.31M | 6.95M | 6.44M | 13.1M | 10.1M |
| EPS | 0.00 | -0.02 | -0.02 | 0.00 | 0.00 | 0.08 | 0.07 | 0.14 | 0.10 |
| Balance Sheet | |||||||||
| Total Assets | 28.9M | 68.1M | 54.9M | 92.0M | 126M | 142M | 155M | 169M | 194M |
| Total Liabilities | 14.1M | 18.2M | 16.5M | 27.9M | 58.9M | 61.8M | 66.8M | 66.4M | 68.6M |
| Shareholders' Equity | 14.7M | 49.9M | 38.4M | 64.1M | 66.7M | 79.7M | 88.0M | 102M | 126M |
| Cash & Short-term Investments | 12.9M | 26.5M | 7.77M | 8.16M | 12.1M | 4.27M | 6.62M | 14.4M | 21.8M |
| Cash Flow | |||||||||
| Operating Cash Flow | -2.30M | -7.41M | -9.32M | -2.09M | -6.08M | 5.44M | 10.7M | 20.0M | 22.1M |
| Capital Expenditure | 27.9M | 23.0M | 9.18M | 30.6M | 15.1M | 9.88M | 7.47M | 6.36M | 16.3M |
| Free Cash Flow | -16.1M | -29.7M | -18.1M | -33.2M | -21.5M | -4.44M | 3.21M | 13.7M | 5.78M |
| Ratios | |||||||||
| ROE | -14.3% | -24.7% | -32.5% | -2.4% | 3.5% | 8.7% | 7.3% | 12.8% | 8.0% |
| ROA | -7.3% | -18.1% | -22.8% | -1.7% | 1.8% | 4.9% | 4.2% | 7.8% | 5.2% |
| Net Profit Margin | -488.4% | -587.3% | -504.4% | -9.4% | 6.4% | 12.1% | 7.9% | 12.2% | 8.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Cannara Biotech Inc dividends
Cannara Biotech Inc has not paid dividends in the last 8 fiscal years.
Last stock split: 1:10 on Feb 13, 2023.
Who owns Cannara Biotech Inc
- Insiders 50.16%
- Institutions 0.27%
- Public & others 49.58%
- Shares outstanding 98.8M
- Free float 45.2M
Cannara Biotech Inc company profile
- Company name
- Cannara Biotech Inc
- Ticker
- LOVFF.US
- ISIN
- CA13765U2002
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 452
- Fiscal year end
- August
- Address
- 333 Decarie Blvd., Saint-Laurent, QC, Canada, H4N 3M9
- Phone
- 514 543 4200
- Website
- cannara.ca
About Cannara Biotech Inc
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name. The company sells its products through wholesalers and online merchandisers. In addition, it engages in the real estate operations. Cannara Biotech Inc. was incorporated in 2017 and is headquartered in Saint-Laurent, Canada.
Cannara Biotech Inc management
10- Mr. Zohar KrivorotFounder, CEO & Chairman · born 1977
- Mr. Nicholas Sosiak C.A., CPAChief Operating Officer
- Mr. Avi KrivorotChief Technology Officer
- Mr. Nicholas Fozard CPAChief Financial Officer
- Mr. Scott CarrollVice President of Investor Relations & Commercial Strategy
- Mr. Brian ShermanGeneral Counsel & VP Legal Affairs
- Nick Van DamVice President of Sales
- Ms. Sabrina SalvoVice President of Marketing
- Ms. France LandryVice President of Human Resources
- Etienne LedouxExecutive Officer